BioSpace News Archive

Industry veterans Judy Lewent, Jonathan MacQuitty, and Howie Rosen bring to twoXAR nearly 90 years of combined R&D and commercial experience in the biopharmaceutical sector.

This trial had two prospectively defined co-primary endpoints.

The results of the earlier study showed significant differences in favour of two higher doses of LMTX when taken as monotherapy compared with the intended 4 mg control dose taken as monotherapy or as add-on therapy to currently approved treatments for Alzheimer’s disease in pre-specified post hoc analyses.

In the current trial, the research team will inject a commonly used sonographic microbubble solution into the bloodstream of a patient with a malignant brain tumor.

CE marking allows for widespread commercialization of Aidoc’s solution in Europe.

Mycolog II Cream is indicated for the treatment of cutaneous candidiasis.

Brian McGee, Dr. James H. Anderson, Jr., MD, Dr. Craig Eagle, MD, and Dr. Gary H. Lyman, MD, MPH were elected as independent members of the Company’s Board of Directors.

Net proceeds to the Company from the Registered Direct Offering are approximately $0.49 million, which Jaguar intends to use for the ongoing commercialization of Mytesi, the Company’s lead prescription drug product, and for working capital and general corporate purposes.

This success was validated by an independent report from Lewin Group, which showed a nearly nine percent decrease in hospitalization rates for these patients during the same time.

Orchard Therapeutics announces today that it has acquired an exclusive license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B from The University of Manchester, UK.